Cargando…

Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes

Until recently, the most standard treatment for sensorineural or sudden hearing loss, which is caused by inner ear damage or deterioration, has been systemic oral steroid administration. In recent, intratympanic steroid injections such as dexamethasone have been used for the treatment of sudden hear...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Jin Woo, Li, Hui, Lee, Jung Hun, Hwang, Yu-Jung, Dan, Kisoon, Park, Moo Kyun, Han, Dohyun, Suh, Myung-Whan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892634/
https://www.ncbi.nlm.nih.gov/pubmed/36744248
http://dx.doi.org/10.3389/fphar.2023.1081724
_version_ 1784881362782650368
author Jung, Jin Woo
Li, Hui
Lee, Jung Hun
Hwang, Yu-Jung
Dan, Kisoon
Park, Moo Kyun
Han, Dohyun
Suh, Myung-Whan
author_facet Jung, Jin Woo
Li, Hui
Lee, Jung Hun
Hwang, Yu-Jung
Dan, Kisoon
Park, Moo Kyun
Han, Dohyun
Suh, Myung-Whan
author_sort Jung, Jin Woo
collection PubMed
description Until recently, the most standard treatment for sensorineural or sudden hearing loss, which is caused by inner ear damage or deterioration, has been systemic oral steroid administration. In recent, intratympanic steroid injections such as dexamethasone have been used for the treatment of sudden hearing loss as well. It is injected into the tympanic cavity through its membrane and is expected to diffuse over the round window located between the tympanic cavity and the inner ear. However, in clinical situations, the delivery time of steroids to the inner ear is shorter than 24 h, which does not allow for a sufficient therapeutic effect. Therefore, we applied a previously invented dual viscosity mixture vehicle (DVV) for intratympanic dexamethasone to a guinea pig model, which could reduce the side effects of systemic steroid administration with sufficient dwelling time for the treatment of hearing loss, and we investigated the physiological changes with a global proteomic approach. In this study, we extracted perilymph in three different conditions from guinea pigs treated with dexamethasone-embedded DVV, dexamethasone mixed in saline, and control groups to compare proteomic changes using tandem mass spectrometry analysis. After liquid chromatography coupled tandem mass spectrometry (LC-MS/MS) analysis, we first identified 46 differentially expressed proteins (DEPs) that were statistically significant after one-way ANOVA multiple-sample test. We also performed pairwise comparisons among each group to identify DEPs closely related to the treatment response of dexamethasone-embedded DVV. Gene ontology enrichment analysis showed that these DEPs were mostly related to inflammation, immune, actin remodeling, and antioxidant-related processes. As a result, the proteome changes in the DVV-treated groups revealed that most upregulated proteins activate the cell proliferation process, and downregulated proteins inhibit apoptosis and inflammatory reactions. Moreover, the reactive oxygen process was also regulated by DEPs after DVV treatment.
format Online
Article
Text
id pubmed-9892634
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98926342023-02-03 Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes Jung, Jin Woo Li, Hui Lee, Jung Hun Hwang, Yu-Jung Dan, Kisoon Park, Moo Kyun Han, Dohyun Suh, Myung-Whan Front Pharmacol Pharmacology Until recently, the most standard treatment for sensorineural or sudden hearing loss, which is caused by inner ear damage or deterioration, has been systemic oral steroid administration. In recent, intratympanic steroid injections such as dexamethasone have been used for the treatment of sudden hearing loss as well. It is injected into the tympanic cavity through its membrane and is expected to diffuse over the round window located between the tympanic cavity and the inner ear. However, in clinical situations, the delivery time of steroids to the inner ear is shorter than 24 h, which does not allow for a sufficient therapeutic effect. Therefore, we applied a previously invented dual viscosity mixture vehicle (DVV) for intratympanic dexamethasone to a guinea pig model, which could reduce the side effects of systemic steroid administration with sufficient dwelling time for the treatment of hearing loss, and we investigated the physiological changes with a global proteomic approach. In this study, we extracted perilymph in three different conditions from guinea pigs treated with dexamethasone-embedded DVV, dexamethasone mixed in saline, and control groups to compare proteomic changes using tandem mass spectrometry analysis. After liquid chromatography coupled tandem mass spectrometry (LC-MS/MS) analysis, we first identified 46 differentially expressed proteins (DEPs) that were statistically significant after one-way ANOVA multiple-sample test. We also performed pairwise comparisons among each group to identify DEPs closely related to the treatment response of dexamethasone-embedded DVV. Gene ontology enrichment analysis showed that these DEPs were mostly related to inflammation, immune, actin remodeling, and antioxidant-related processes. As a result, the proteome changes in the DVV-treated groups revealed that most upregulated proteins activate the cell proliferation process, and downregulated proteins inhibit apoptosis and inflammatory reactions. Moreover, the reactive oxygen process was also regulated by DEPs after DVV treatment. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9892634/ /pubmed/36744248 http://dx.doi.org/10.3389/fphar.2023.1081724 Text en Copyright © 2023 Jung, Li, Lee, Hwang, Dan, Park, Han and Suh. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Jung, Jin Woo
Li, Hui
Lee, Jung Hun
Hwang, Yu-Jung
Dan, Kisoon
Park, Moo Kyun
Han, Dohyun
Suh, Myung-Whan
Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes
title Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes
title_full Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes
title_fullStr Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes
title_full_unstemmed Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes
title_short Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes
title_sort dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ros and inflammation related proteomes
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892634/
https://www.ncbi.nlm.nih.gov/pubmed/36744248
http://dx.doi.org/10.3389/fphar.2023.1081724
work_keys_str_mv AT jungjinwoo dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes
AT lihui dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes
AT leejunghun dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes
AT hwangyujung dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes
AT dankisoon dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes
AT parkmookyun dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes
AT handohyun dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes
AT suhmyungwhan dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes